In Vitro Dissolution Testing Models of Ocular Implants for Posterior Segment Drug Delivery

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2021 Aug 12

PMID 34382178

Citations 13

Authors

Muhammad Faris Adrianto

Febri Annuryanti

Clive G Wilson

Ravi Sheshala

Raghu Raj Singh Thakur

Affiliations

Soon will be listed here.

Abstract

The delivery of drugs to the posterior segment of the eye remains a tremendously difficult task. Prolonged treatment in conventional intravitreal therapy requires injections that are administered frequently due to the rapid clearance of the drug molecules. As an alternative, intraocular implants can offer drug release for long-term therapy. However, one of the several challenges in developing intraocular implants is selecting an appropriate in vitro dissolution testing model. In order to determine the efficacy of ocular implants in drug release, multiple in vitro test models were emerging. While these in vitro models may be used to analyse drug release profiles, the findings may not predict in vivo retinal drug exposure as this is influenced by metabolic and physiological factors. This review considers various types of in vitro test methods used to test drug release of ocular implants. Importantly, it discusses the challenges and factors that must be considered in the development and testing of the implants in an in vitro setup.

Citing Articles

An exploration of the ocular mysteries linking nanoparticles to the patho-therapeutic effects against keratitis.

Qu S, Zheng S, Muhammad S, Huang L, Guo B J Nanobiotechnology. 2025; 23(1):184.

PMID: 40050881 PMC: 11887204. DOI: 10.1186/s12951-025-03230-3.

Impact of mechanical engineering innovations in biomedical advancements.

Kennedy S, Vasanthanathan A, Jeen Robert R, Vignesh Moorthi Pandian A In Vitro Model. 2025; 3(1):5-18.

PMID: 39872067 PMC: 11756506. DOI: 10.1007/s44164-024-00065-4.

Emerging trends in long-acting sustained drug delivery for glaucoma management.

So Y, Mishra D, Gite S, Sonawane R, Waite D, Shaikh R Drug Deliv Transl Res. 2025; .

PMID: 39786666 DOI: 10.1007/s13346-024-01779-4.

Extended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases.

Wykoff C, Kuppermann B, Regillo C, Chang M, Hariprasad S, Duker J J Vitreoretin Dis. 2024; 8(5):577-586.

PMID: 39318989 PMC: 11418737. DOI: 10.1177/24741264241267065.

Development of ARPE-19-Equipped Ocular Cell Model for In Vitro Investigation on Ophthalmic Formulations.

Sapino S, Chindamo G, Peira E, Chirio D, Foglietta F, Serpe L Pharmaceutics. 2023; 15(10).

PMID: 37896232 PMC: 10610172. DOI: 10.3390/pharmaceutics15102472.

References

Tan L, Orilla W, Hughes P, Tsai S, Burke J, Wilson C . Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles. Invest Ophthalmol Vis Sci. 2010; 52(2):1111-8. DOI: 10.1167/iovs.10-5813. View

Jiang P, Chaparro F, Cuddington C, Palmer A, Ohr M, Lannutti J . Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration. J Control Release. 2020; 320:442-456. DOI: 10.1016/j.jconrel.2020.01.036. View

Zhou F, Li H, Wang K, He Y, Chen Y, Ni X . Finger or Light: Stimulation Sensitivity of Visual Startle in the Coma Recovery Scale-Revised for Disorders of Consciousness. Neurosci Bull. 2018; 34(4):709-712. PMC: 6060208. DOI: 10.1007/s12264-018-0261-3. View

Tamaddon L, Mostafavi S, Karkhane R, Riazi-Esfahani M, Dorkoosh F, Rafiee-Tehrani M . Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis. Adv Biomed Res. 2015; 4:32. PMC: 4333484. DOI: 10.4103/2277-9175.150426. View

Zolnik B, Leary P, Burgess D . Elevated temperature accelerated release testing of PLGA microspheres. J Control Release. 2006; 112(3):293-300. DOI: 10.1016/j.jconrel.2006.02.015. View

Luaces-Rodriguez A, Mondelo-Garcia C, Zarra-Ferro I, Gonzalez-Barcia M, Aguiar P, Fernandez-Ferreiro A . Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration. Int J Pharm. 2019; 573:118767. DOI: 10.1016/j.ijpharm.2019.118767. View

Del Amo E, Rimpela A, Heikkinen E, Kari O, Ramsay E, Lajunen T . Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2016; 57:134-185. DOI: 10.1016/j.preteyeres.2016.12.001. View

Los L, Van der Worp R, van Luyn M, Hooymans J . Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. Invest Ophthalmol Vis Sci. 2003; 44(7):2828-33. DOI: 10.1167/iovs.02-0588. View

Stewart S, Dominguez-Robles J, Donnelly R, Larraneta E . Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications. Polymers (Basel). 2019; 10(12). PMC: 6401754. DOI: 10.3390/polym10121379. View

10.

Schliecker G, Schmidt C, Fuchs S, Ehinger A, Sandow J, Kissel T . In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis. J Control Release. 2003; 94(1):25-37. DOI: 10.1016/j.jconrel.2003.09.003. View

11.

Friedrich S, Cheng Y, Saville B . Finite element modeling of drug distribution in the vitreous humor of the rabbit eye. Ann Biomed Eng. 1997; 25(2):303-14. DOI: 10.1007/BF02648045. View

12.

Bucolo C, Drago F, Salomone S . Ocular drug delivery: a clue from nanotechnology. Front Pharmacol. 2012; 3:188. PMC: 3486627. DOI: 10.3389/fphar.2012.00188. View

13.

Soman N, Banerjee R . Artificial vitreous replacements. Biomed Mater Eng. 2003; 13(1):59-74. View

14.

Radhakrishnan K, Sonali N, Moreno M, Nirmal J, Fernandez A, Venkatraman S . Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins. Drug Discov Today. 2016; 22(2):416-423. DOI: 10.1016/j.drudis.2016.10.015. View

15.

Patel A, Cholkar K, Agrahari V, Mitra A . Ocular drug delivery systems: An overview. World J Pharmacol. 2015; 2(2):47-64. PMC: 4289909. DOI: 10.5497/wjp.v2.i2.47. View

16.

Allababidi S, Shah J . Kinetics and mechanism of release from glyceryl monostearate-based implants: evaluation of release in a gel simulating in vivo implantation. J Pharm Sci. 1998; 87(6):738-44. DOI: 10.1021/js9703986. View

17.

Jackson T, Antcliff R, Hillenkamp J, Marshall J . Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci. 2003; 44(5):2141-6. DOI: 10.1167/iovs.02-1027. View

18.

Lee S, Hughes P, Ross A, Robinson M . Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010; 27(10):2043-53. DOI: 10.1007/s11095-010-0159-x. View

19.

Rodriguez Ramirez M, del Barrio Manso M, Martin Sanchez M . Intravitreal injections: what do patients prefer? Analysis of patient's satisfaction and preferences about where to perform intravitreal injections. Arch Soc Esp Oftalmol. 2014; 89(12):477-83. DOI: 10.1016/j.oftal.2014.05.010. View

20.

Iyer S, Barr W, Karnes H . Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm Drug Dispos. 2006; 27(4):157-70. DOI: 10.1002/bdd.493. View